TP53 and acute lymphoblastic leukemia: In p53-defective Jurkat lymphoblastic leukemia cells, the treatment increased both p73 α and β expression, while decreasing the expression of UHRF-1, DNMT1 and HDAC1 in a dose-dependent manner.